Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
Taking the peptide pinealon gives you three hours of REM sleep that night, and your REM sleep is enriched on the nights that follow.
The finding
What the evidence shows
Pinealon is a real synthetic three amino acid peptide from Russian bioregulator research, but its published work is animal and cell studies on protecting brain tissue, and none of it measures sleep. There is no study showing it lengthens REM sleep in people. The amount described also stands out, because REM is about 25% of a night's sleep for a healthy adult, roughly two hours on an eight hour night, so three hours would be well above typical. This is a personal impression rather than a measured effect.
Read the supporting source · www.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that Taking the peptide pinealon gives you three hours of REM sleep that night, and your REM sleep is enriched on the nights that follow?
Partly. The claim stretches what the evidence shows. Pinealon is a real synthetic three amino acid peptide from Russian bioregulator research, but its published work is animal and cell studies on protecting brain tissue, and none of it measures sleep. There is no study showing it lengthens REM sleep in people. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 1:54:20. The supporting source is ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.